Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes

Kazmin, 2007, Risks of statin use during pregnancy: a systematic review, J Obstet Gynaecol Can, 906, 10.1016/S1701-2163(16)32656-1 Henshaw, 1998, Unintended pregnancy in the United States, Fam Plann Perspect, 30, 24, 10.2307/2991522 Topol, 2004, Intensive statin therapy—a sea change in cardiovascular prevention, N Engl J Med, 350, 1562, 10.1056/NEJMe048061 Wise, 1990, Simvastatin (MK-0733) oral teratogenicity study in rabbits, Yakuri to Chiryo, 39, 159 Minsker, 1983, Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Teratology, 28, 449, 10.1002/tera.1420280316 Henck, 1998, Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats, Toxicol Sci, 41, 88, 10.1093/toxsci/41.1.88 Manson, 1996, Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy, Reprod Toxicol, 10, 439, 10.1016/S0890-6238(96)00130-X Pollack, 2005, Pregnancy outcomes after maternal exposure to simvastatin and lovastatin, Birth Defects Res A Clin Mol Teratol, 73, 888, 10.1002/bdra.20181 Edison, 2004, Mechanistic and epidemiologic considerations in the evaluation of adverse birth outscomes following gestational exposure to statins, Am J Med Genet, 131A, 287, 10.1002/ajmg.a.30386 Edison, 2005, Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly [letter], N Engl J Med, 352, 2759, 10.1056/NEJM200506303522622 Gibb, 2005, Statin drugs and congenital anomalies [letter], Am J Med Genet, 135A, 230, 10.1002/ajmg.a.30685 Hacker, 1998 Montoudis, 1999, Impact of a cholesterol enriched diet on maternal and fetal plasma lipids and fetal deposition in pregnant rabbits, Life Sci, 64, 2439, 10.1016/S0024-3205(99)00201-5 Edison, 2005, Reply to “Statin drugs and congenital anomalies” by Gibb and Scialli [letter], Am J Med Genet, 135A, 232, 10.1002/ajmg.a.30686 Honein, 1999, Evaluation of selected characteristics of pregnancy drug registries, Teratology, 60, 356, 10.1002/(SICI)1096-9926(199912)60:6<356::AID-TERA8>3.0.CO;2-B Koren, 2006, Major malformations with valproic acid, Can Fam Physician, 52, 441 Holmes, 2001, The teratogenicity of anticonvulsant drugs, N Engl J Med, 344, 1132, 10.1056/NEJM200104123441504